NCT03685331: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer

NCT03685331
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have germline or somatic BRCA mutation; Prior treatment with 0-2 prior lines of chemotherapy for MBC- see trial for details
Exclusions: Patients with symptomatic uncontrolled brain metastases; Patients who have had prior treatment with a PARP inhibitor or CDK4/6 inhibitor
https://ClinicalTrials.gov/show/NCT03685331

Comments are closed.

Up ↑